Интерлейкин-6 и диабетическая нефропатия: патогенетические связи, мишени для нефропротекции

Автор: Пчелин И.Ю., Байрашева В.К., Шишкин А.Н., Василькова О.Н., Худякова Н.В.

Журнал: Juvenis scientia @jscientia

Рубрика: Медицинские науки

Статья в выпуске: 12, 2017 года.

Бесплатный доступ

В статье представлены данные о роли интерлейкина-6 (IL-6) в развитии диабетической нефропатии (ДН) и патогенетически связанных с ней состояний. Рассмотрены эффекты, обусловленные связыванием IL-6 с мембранным рецептором (IL-6R) и растворимым рецептором (sIL-6R). Проанализированы результаты экспериментальных и клинических исследований, направленных на изучение взаимосвязи IL-6 с ожирением, инсулинорезистентностью, нефросклерозом, кардиомиопатией и анемией. Обсуждаются различные стратегии противовоспалительной терапии и нефропротекции.

Интерлейкин-6, сахарный диабет, инсулин, инсулинорезистентность, хроническая болезнь почек, диабетическая нефропатия, тоцилизумаб

Короткий адрес: https://readera.ru/14110446

IDR: 14110446

Список литературы Интерлейкин-6 и диабетическая нефропатия: патогенетические связи, мишени для нефропротекции

  • Ni W.J., Tang L.Q., Wei W. Research progress in signalling pathway in diabetic nephropathy//Diabetes Metab. Res. Rev. 2015. Vol. 31. Pp. 221-233.
  • Zheng Z., Zheng F. Immune Cells and Inflammation in Diabetic Nephropathy//J. Diabetes Res. 2016. ID1841690.
  • Kaul K., Hodgkinson A., Tarr J.M. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?//Curr. Diab. Rev. 2010. Vol. 6. Pp. 294-303.
  • Navarro-Gonzalez J.F., Mora-Fernandez C., De Fuentes M.M. et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy//Nat. Rev. Nephrol. 2011. Vol. 7. Pp. 327-340.
  • Wada J., Makino H. Inflammation and the pathogenesis of diabetic nephropathy//Clin. Sci. (London). 2013 Vol. 124. Pp. 139-152.
  • National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update//Am. J. Kidney Dis. 2012. Vol. 60. Pp. 850-886.
  • ERBP Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR №45 mL/min)//Nephrol. Dial. Transplant. 2015. Vol. 30. Suppl. 2. Pp. ii1-ii142.
  • Eder K., Baffy N., Falus A., Fulop A.K. The major inflammatory mediator interleukin-6 and obesity//Inflamm. Res. 2009. Vol. 58. Pp. 727-736.
  • Maggio M., Guralnik J.M., Longo D.L., Ferrucci L. Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway//J. Gerontol. A. Biol. Sci. Med. Sci. 2006. Vol. 61. Pp. 575-584.
  • Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases//Trends Immunol. 2012 Vol. 33. Pp. 571-577.
  • Scheller J., Garbers C., Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities//Semin. Immunol. 2014. Vol. 26. Pp. 2-12.
  • Друцкая М.С., Носенко М.А, Атретханы К.-С.Н. и соавт. Интерлейкин-6 -от молекулярных механизмов передачи сигнала к физиологическим функциям и терапевтическим мишеням//Молекулярная биология. 2015. Т. 49. №6. С. 937-943.
  • Chalaris A., Garbers C., Rabe B. et al. The soluble interleukin 6 receptor: generation and role in inflammation and cancer//Eur. J. Cell. Biol. 2011. Vol. 90. Pp. 484-494.
  • Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6//Biochim. Biophys. Acta. 2011. Vol. 1813. Pp. 878-888.
  • Andersson C.X., Sopasakis V.R., Wallerstedt E., Smith U. Insulin antagonizes interleukin-6 signaling and is anti-inflammatory in 3T3-L1 adipocytes//J. Biol. Chem. 2007. Vol. 282. Pp. 9430-9435.
  • Andreozzi F., Laratta E., Procopio C. et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells//Mol. Cell. Biol. 2007. Vol. 27. Pp. 2372-2383.
  • Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes//Diabetes. 2002. Vol. 51. Pp. 3391-3399.
  • Weber M.M., Michl P., Auernhammer C.J., Engelhardt D. Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells//Endocrinology. 1997. Vol. 138. Pp. 2207-2210.
  • Barnes T.M., Otero Y.F., Elliott A.D. et al. Interleukin-6 amplifies glucagon secretion: Coordinated control via the brain and pancreas//Am. J. Physiol. Endocrinol. Metab. 2014. Vol. 307. Pp. E896-E905.
  • Sahraoui A., Kloster-Jensen K., Ueland T. et al. Anakinra and tocilizumab enhance survival and function of human islets during culture: implications for clinical islet transplantation//Cell Transplant. 2014. Vol. 23. Pp. 1199-1211.
  • Navarro-Gonzalez J. F., Mora-Fernandez C. The Role of Inflammatory Cytokines in Diabetic Nephropathy//J. Am. Soc. Nephrol. 2008. Vol. 19. P. 433-442.
  • Fornoni A., Ijaz A., Tejada T. et al. Role of Inflammation in Diabetic Nephropathy//Curr. Diab. Rev. 2008. Vol. 4. Pp. 10-17.
  • Navarro J.F., Milena F.J., Mora C. et al. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration//Am. J. Nephrol. 2007. Vol. 26. Pp. 562-570.
  • Ayhan M., Guney E., Soysalatile N. et al. Preventive effects of alpha-lipoic acid on diabetic nephropathy in a rat model//Acta Med. Mediterr. 2014. Vol. 30. Pp. 1221-1225.
  • Li R., Uttarwar L., Gao B. et al. High Glucose Up-regulates ADAM17 through HIF-1α in Mesangial Cells//J. Biol. Chem. 2015. Vol. 290. Pp. 21603-21614.
  • Obama T., Takayanagi T., Kobayashi T. et al. Vascular induction of a disintegrin and metalloprotease 17 by angiotensin II through hypoxia inducible factor 1α//Am. J. Hypertens. 2015. Vol. 28. Pp. 10-14.
  • Salem E.S., Grobe N., Elased K.M. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice//Am. J. Physiol. Renal. Physiol. 2014. Vol. 306. Pp. F629-F639.
  • Riera M., Anguiano L., Clotet S. et al. Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD diabetic mice beyond proteinuria//Am. J. Physiol. Renal Physiol. 2015. Vol. 310. Pp. F534-F546.
  • Raucci A., Cugusi S., Antonelli A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)//FASEB J. 2008. Vol. 22. Pp. 3716-3727.
  • Худякова Н.В., Пчелин И.Ю., Шишкин А.Н. Иванов Н.В., Василькова О.Н. Гипергомоцистеинемия и кардиоренальный анемический синдром при сахарном диабете//Нефрология. 2015. Т. 19. №6. С. 20-27.
  • Ray A., Huisman M.V., Tamsma J.T. et al. The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus//Eur. J. Int. Med. 2009. Vol. 20. Pp. 253-260.
  • Zeng S.Y., Chen X., Chen S.R. et al. Upregulation of Nox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression//Can. J. Cardiol. 2013. Vol. 29. Pp. 1310-1319.
  • Van der Vorst E.P., Jeurissen M., Wolfs I.M. et al. Myeloid A disintegrin and metalloproteinase domain 10 deficiency modulates atherosclerotic plaque composition by shifting the balance from inflammation toward fibrosis//Am. J. Pathol. 2015. Vol. 185. Pp. 1145-1155.
  • Shitomi Y., Thøgersen I.B., Ito N. et al. ADAM10 controls collagen signaling and cell migration on collagen by shedding the ectodomain of discoidin domain receptor 1 (DDR1)//Mol. Biol. Cell. 2015. Vol. 26. Pp. 659-673.
  • Newby A.C. Proteinases and plaque rupture: unblocking the road to translation//Curr Opin Lipidol. 2014. Vol. 25. Pp. 358-366.
  • Yang L.N., Zhang P., Tang F. et al. Correlation between hepcidin level and renal anemia//Genet. Mol. Res. 2014. Vol. 13. Pp. 7407-7410.
  • Quin C., Xiao Y., Zhong Q. et al. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism//Chin. J. Traumatol. 2008. Vol. 11. Pp. 352-358.
  • Zhang J., Zou Y.R., Zhong X. et al. Erythropoietin pretreatment ameliorates renal ischaemia-reperfusion injury by activating PI3K/Akt signalling//Nephrology (Carlton). 2015. Vol. 20. Pp. 266-272.
  • Пчелин И.Ю., Шишкин А.Н., Коробицын Л.П. Проблема соотношения пользы и риска терапии средствами, стимулирующими эритропоэз, при диабетической нефропатии//Нефрология. 2010. Т. 14. № 3. С. 32-36.
  • Papaoikonomou S., Tentolouris N., Tousoulis D. et al. The association of the 174G>C polymorphism of interleukin 6 gene with diabetic nephropathy in patients with type 2 diabetes mellitus//J. Diabetes Complications. 2013. Vol. 27. Pp. 576-579.
  • Shikano M., Sobajima H., Yoshikawa H. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy//Nephron. 2000. Vol. 85. Pp. 81-85.
  • Пчелин И.Ю., Худякова Н.В., Шишкин А.Н. Взаимосвязь интерлейкина-6 и компонентов кардиоренального анемического синдрома при диабетической нефропатии//Вестник Санкт-Петербургского университета. Серия 11. Медицина. 2016. Вып. 2. С. 4-12.
  • Svensson M.K., Eriksson J.W. Change in the amount of body fat and IL-6 levels is related to altered insulin sensitivity in type 1 diabetes patients with or without diabetic nephropathy//Horm. Metab. Res. 2011. Vol. 43. Pp. 209-215.
  • Hruby Z., Sowiński D. Urinary excretion of growth factors/cytokines and progression of diabetic nephropathy with overt proteinuria//Adv. Clin. Exp. Med. 2003. Vol. 12. Pp. 723-729.
  • Noori N., Tabibi H., Hosseinpanah F. et al. Effects of combined administration of lipoic acid and pyridoxine on serum systemic and vascular inflammatory factors in patients with diabetic nephropathy //Iran. J. Endocrinol. Metab. 2010. Vol. 12. Pp. 194.
  • Nakahara H., Nishimoto N. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases//Endocr. Metab. Immune Disord. Drug Targets. 2006. Vol. 6. Pp. 373-381.
  • Kang S., Tanaka T., Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody//Int. Immunol. 2015. Vol. 27. Pp. 21-29.
  • Насонов Е.Л. Новые направления фармакотерапии ревматических заболеваний -ингибиция интерлейкина 6 и интерлейкина 17//Современная ревматология. 2013. №3. С. 5-14.
  • U.S. National Library of Medicine Clinical Trials Database. URL: https://clinicaltrials.gov.
  • Williams J.M., Zhang J., North P. et al. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy//Am. J. Physiol. Renal Physiol. 2011. Vol. 300. Pp. F983-F998.
Еще
Статья научная